Interestingly, only IFNα2a/b is approved for clinical treatment against chronic viral infections, whereas IFNβ is only used therapeutically against multiple sclerosis (MS), but not as an antiviral drug. This evidence concerns the gene IFNB1 and myeloid sarcoma.